BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22080849)

  • 21. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
    Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
    Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre.
    Bazarbashi S; Aseafan M; Elgazzar T; Alkhayat M; Alghabban A; Abdelgawad MI; Alshamsan B; Alshibany A; Elhassan T; Aljubran A; Alzahrani A; Alhindi H; Raef H
    BMC Endocr Disord; 2023 Apr; 23(1):74. PubMed ID: 37029347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.
    Goroshi M; Bandgar T; Lila AR; Jadhav SS; Khare S; Shrikhande SV; Uchino S; Dalvi AN; Shah NS
    Fam Cancer; 2016 Oct; 15(4):617-24. PubMed ID: 26905068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary malignancy in patients with sporadic neuroendocrine neoplasia.
    Krausch M; Raffel A; Anlauf M; Schott M; Lehwald N; Krieg A; Kröpil F; Cupisti K; Knoefel WT
    Endocrine; 2013 Oct; 44(2):510-6. PubMed ID: 23494366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
    Guo LJ; Wang CH; Tang CW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction.
    Van Hootegem P; Borbath I; Verslype C
    Acta Gastroenterol Belg; 2009; 72(1):27-8. PubMed ID: 19402367
    [No Abstract]   [Full Text] [Related]  

  • 28. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indications for genetic study in gastro-entero-pancreatic and thoracic neuroendocrine tumors.
    Araujo-Castro M
    Endocrinol Diabetes Nutr (Engl Ed); 2023 Mar; 70 Suppl 1():63-73. PubMed ID: 36396595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients.
    de Laat JM; Pieterman CR; van den Broek MF; Twisk JW; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3325-33. PubMed ID: 24915123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
    Koch C; Koca E; Filmann N; Husmann G; Bojunga J
    Medicine (Baltimore); 2021 Sep; 100(37):e27276. PubMed ID: 34664885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
    Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
    Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
    Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
    Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
    Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
    Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
    Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
    Das S; Dasari A
    Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.